DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its Comprehensive Transformation Pl ...

ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 31, 2025. Management Commentary "The third quarter and first nine months of fiscal ...

SALT LAKE CITY, May 15, 2025 (GLOBE NEWSWIRE) -- OMNIQ CORP. (OTCMKTS: OMQS) ("omniQ" or "the Company"), reports a first quarter 2025 revenue of $19.9 million, which signifies an 8.7 percent increase Year-over-Year. FINANCIAL SUMMARY In Q1 2025, the Company reported revenue of $19.9 million, marking an increase of 8.7 percent compared to $18.3 million in Q1 2024. Net loss for the quarter remained steady at $2.1 million, unchanged from the same period last year. Basic loss per share from continuing operation ...

By letter received on May 13, 2025, the simplified joint-stock company Indépendance AM (20 avenue Franklin D. Roosevelt, 75008 Paris), acting on behalf of funds under its management, declared that on May 8, 2025, it had crossed upwards the thresholds of 5% of the share capital and voting rights of Sword Group. It stated that it holds, on behalf of the aforementioned funds, 512,929 Sword Group shares, representing the same number of voting rights, i.e., 5.37% of the company’s share capital and voting rights ...

MATAWAN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Hovnanian Enterprises, Inc. (NYSE: HOV), a leading national homebuilder across the United States, announced the signing of a strategic Memorandum of Understanding (MOU) between its Middle East subsidiary, K. Hovnanian M.E. Investments, LLC, and Saudi Arabia’s leading real estate developer NHC. The MOU was signed by Mr. Mohammad Albuty, Chief Executive Officer of NHC, and Ara K. Hovnanian, Chairman of the Board, President, and Chief Executive Officer of Hovnani ...

May 15, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any Eligible Projects as defined in Philips’ Sustaina ...

CARLSBAD, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (“AppTech or the “Company”) (NASDAQ: APCX), a fintech company, today announced its First Quarter 2025 financial results. The Company reported an operating loss of $2.6 million ($0.08 per share) versus a $3.0 million loss in the same quarter of 2024 ($0.13 per share). The cash basis loss was $1.8 million versus $2.2 million in 2024. AppTech seeks to further enhance operating efficiency and has added revenue sources to achieve breakeven ...

CHICAGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Income Statement Cosmos Health delivered ...

VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Lancaster Resources Inc. (CSE:LCR) (OTC:LANRF) (FRA:6UF0) (“Lancaster”), is pleased to announce that the vendor of the Lake Cargelligo Gold Project received final approval from the State of New South Wales for an Exploration License at the Lake Cargelligo Gold Project (the "Project") in the famed Cobar mining district of New South Wales, Australia. The Project encompasses over 28,768 hectares under a single Exploration License (EL 9775) for Group ...

Core Viewpoint - A federal court jury found Amgen liable for antitrust violations, awarding Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages due to Amgen's anticompetitive practices that hindered competition for Praluent [1][3]. Summary by Relevant Sections Antitrust Violations - Amgen was found to have violated multiple laws, including the Clayton Act and Sherman Act, by using cross-therapeutic bundled rebates to favor Repatha over Praluent, thereby preventing fair competition [1][2]. Jury Verdict and Damages - The jury awarded Regeneron a total of $406.8 million, comprising $135.6 million in compensatory damages and $271.2 million in punitive damages aimed at deterring similar future conduct [3]. Company Statements - Regeneron emphasized the importance of fair competition in the biotech industry, stating that anticompetitive tactics undermine patient access to innovative therapies and hinder medical advancements [4]. Product Information - Praluent, developed by Regeneron and Sanofi, is designed to lower LDL cholesterol levels by inhibiting PCSK9, and is approved in 60 countries [6][7]. Technology and Innovation - Regeneron's proprietary VelocImmune technology has been instrumental in developing fully human monoclonal antibodies, contributing to a significant portion of FDA-approved treatments [8][9].